Dennis Schmidt Pedersen has been appointed Senior Vice President Human Resources at Swedish Orphan Biovitrum AB (publ) (Sobi). Schmidt Pedersen joins Sobi from global pharmaceutical company Takeda where he has held the position as Director Human Resources, Northern Europe.
Schmidt Pedersen has a strong track record of leading positions in several international companies including Genzyme, Ferring Pharmaceuticals and A.P. Møller-Mærsk. He brings expertise in the transformation of local HR models to more integrated international operating models; developing and implementing regional and international HR processes, guidelines and policies; and cementing the role of people and talent management as an integrated part of the business internationally.
"We are delighted to welcome Dennis to Sobi", said Geoffrey McDonough, President and CEO. "Dennis will help us to build the capacity and reach of our increasingly international organization, and to support the expansion of the cross-functional teams needed to address the opportunities in our current business and pipeline."
Schmidt Pedersen will join Sobi in October, 2013.
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (SOBI.ST) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
|For more information - not for publication|
|Media relations||Investor relations|
|Oskar Bosson, Head of Communications||Jörgen Winroth, Vice President, Head of Investor Relations|
|T: +46 70 410 71 80||T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135|
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE